RMD - ResMed
237.27
| Index: | S&P 500 | P/E: | 31.45 | EPS (ttm): | 7.54 | Insider Own: | 0.79% | Shs Outstand: | 146.78M | Perf Week: | -0.52% |
| Market Cap: | 35.69B | Forward P/E: | 22.89 | EPS next Y: | 10.36 | Insider Trans: | -12.17% | Shs Float: | 145.64M | Perf Month: | -1.77% |
| Income(ttm): | 1.11B | PEG: | 1.85 | EPS next Q: | 2.32 | Inst Own: | 61.44% | Short Float: | 5.18% | Perf Quarter: | -3.62% |
| Revenue(ttm): | 4.81B | P/S: | 7.42 | EPS this Y: | 21.80% | Inst Trans: | 0.46% | Short Ratio: | 8.14 | Perf Half Y: | 30.23% |
| Book/sh: | 35.39 | P/B: | 6.70 | EPS next Y: | 10.22% | ROA: | 15.94% | Short Interest: | 7.54M | Perf Year: | 36.39% |
| Cash/sh: | 2.83 | P/C: | 83.70 | EPS next 5Y: | 17.00% | ROE: | 23.56% | 52W Range: | 164.12 - 260.49 | Perf YTD: | 37.93% |
| Dividend Est.: | 2.20 (0.93%) | P/FCF: | 26.37 | EPS past 5Y: | 19.83% | ROI: | 18.53% | 52W High: | -8.91% | Beta: | 0.70 |
| Dividend TTM: | 2.02 (0.85%) | Quick Ratio: | 1.91 | Sales past 5Y: | 12.49% | Gross Margin: | 56.72% | 52W Low: | 44.57% | ATR (14): | 6.19 |
| Dividend Ex-Date: | Nov 07, 2024 | Current Ratio: | 2.92 | EPS Y/Y TTM: | 22.74% | Oper. Margin: | 30.84% | RSI (14): | 45.38 | Volatility: | 3.28% 2.25% |
| Employees: | 9980 | Debt/Eq: | 0.16 | Sales Y/Y TTM: | 9.88% | Profit Margin: | 23.15% | Recom: | 2.12 | Target Price: | 259.55 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.16 | EPS Q/Q: | 41.80% | Payout: | 27.75% | Rel Volume: | 3.30 | Prev Close: | 231.58 |
| Sales Surprise: | 3.32% | EPS Surprise: | 7.10% | Sales Q/Q: | 11.08% | Earnings: | Oct 24 AMC | Avg Volume: | 925.39K | Price: | 237.27 |
| SMA20: | -2.35% | SMA50: | -2.18% | SMA200: | 7.86% | Undervalued: 9.39% | Volume: | 3,053,157 | Change: | 2.46% | |
Graham Classic formula value: 287.75
(P/E=8 * 1g) Min value: 169.27
(current P/E * 2g) Max value: 443.14
Average value: 300.05
ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.